Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRONGBONE
2024-520372-10-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteopenia and osteoporosis comparing Everolimus + resistance training with Placebo + resistance training (2 arms). Primary endpoint: Percentage change in circulating P1NP at 24 weeks vs baseline. Planned start Jul 2025; status: authorised.
02
Drugs
everolimus
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on 2024-520372-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520372-10-00.